Concept Proven: Array Hits Analgesic Endpoint in Phase II
Array BioPharma Inc.'s p38-alpha kinase inhibitor, ARRY-797, hit its primary endpoint of reducing pain more than placebo in a Phase II proof-of-concept trial in 157 patients with knee pain due to osteoarthritis. Enrolled patients suffered moderate-to-severe pain in spite of the use of nonsteroidal anti-inflammatory drugs (NSAIDs).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter